TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sisram Medical Ltd. ( (HK:1696) ) has provided an announcement.
Sisram Medical Ltd announced strong market momentum in Q3 2025, driven by increased demand in China, South Korea, and Thailand. The company reported a healthy double-digit year-on-year growth in unaudited revenue, with significant orders for its Alma Harmony platform. The company plans to expand the Soprano family in APAC and Universkin sales in the U.S., while preparing for the DAXXIFY launch in China.
The most recent analyst rating on (HK:1696) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
More about Sisram Medical Ltd.
Sisram Medical Ltd, incorporated in Israel, operates in the medical technology industry. The company focuses on providing advanced medical aesthetic solutions, with key products including the Alma Harmony multi-modal platform and the Soprano family of products. It targets markets primarily in the APAC region and the U.S.
Average Trading Volume: 1,683,204
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.19B
For detailed information about 1696 stock, go to TipRanks’ Stock Analysis page.